- Home
- TERN vs ORKA Comparison
TERN vs ORKA Comparison
Compare TERN & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TERN
- ORKA
- Stock Information
- Founded
- TERN 2017
- ORKA 2004
- Country
- TERN United States
- ORKA United States
- Employees
- TERN N/A
- ORKA N/A
- Industry
- TERN Biotechnology: Pharmaceutical Preparations
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- TERN Health Care
- ORKA Health Care
- Exchange
- TERN Nasdaq
- ORKA Nasdaq
- Market Cap
- TERN 634.5M
- ORKA 580.3M
- IPO Year
- TERN 2021
- ORKA N/A
- Fundamental
- Price
- TERN $7.22
- ORKA $16.35
- Analyst Decision
- TERN Buy
- ORKA Strong Buy
- Analyst Count
- TERN 6
- ORKA 8
- Target Price
- TERN $13.99
- ORKA $40.43
- AVG Volume (30 Days)
- TERN 1.2M
- ORKA 151.0K
- Earning Date
- TERN 08-05-2025
- ORKA 08-11-2025
- Dividend Yield
- TERN N/A
- ORKA N/A
- EPS Growth
- TERN N/A
- ORKA N/A
- EPS
- TERN N/A
- ORKA N/A
- Revenue
- TERN N/A
- ORKA N/A
- Revenue This Year
- TERN N/A
- ORKA N/A
- Revenue Next Year
- TERN N/A
- ORKA N/A
- P/E Ratio
- TERN N/A
- ORKA N/A
- Revenue Growth
- TERN N/A
- ORKA N/A
- 52 Week Low
- TERN $1.87
- ORKA $5.49
- 52 Week High
- TERN $11.40
- ORKA $31.13
- Technical
- Relative Strength Index (RSI)
- TERN 59.36
- ORKA 61.56
- Support Level
- TERN $6.78
- ORKA $14.70
- Resistance Level
- TERN $7.78
- ORKA $16.12
- Average True Range (ATR)
- TERN 0.49
- ORKA 1.00
- MACD
- TERN -0.02
- ORKA 0.06
- Stochastic Oscillator
- TERN 63.82
- ORKA 81.07
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.